登录
 机构网站
  1. 首页
  2. 情报产品
  3. 快讯详情

《Nature，4月21日，The potential danger of suboptimal antibody responses in COVID-19》

  • 来源专题：COVID-19科研动态监测
  • 编译者： zhangmin
  • 发布时间：2020-04-22

  • The potential danger of suboptimal antibody responses in COVID-19

    Akiko Iwasaki & Yexin Yang

    Nature Reviews Immunology (2020)

    There is a desperate need for effective therapies and vaccines for SARS-CoV-2 to mitigate the growing economic crisis that has ensued from societal lockdown. Vaccines are being developed at an unprecedented speed and are already in clinical trials, without preclinical testing for safety and efficacy. Yet, safety evaluation of candidate vaccines must not be overlooked.

  • 原文来源：https://www.nature.com/articles/s41577-020-0321-6
125浏览量
原文链接
相关报告

  • 《Nature，4月29日，Antibody responses to SARS-CoV-2 in patients with COVID-19》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-30
    • Antibody responses to SARS-CoV-2 in patients with COVID-19 Quan-Xin Long, Bai-Zhong Liu, […]Ai-Long Huang Nature Medicine (2020) Abstract We report acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19. Within 19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G (IgG). Seroconversion for IgG and IgM occurred simultaneously or sequentially. Both IgG and IgM titers plateaued within 6 days after seroconversion. Serological testing may be helpful for the diagnosis of suspected patients with negative RT–PCR results and for the identification of asymptomatic infections.
    113浏览量
    原文链接

  • 《Nature，4月23日，Complement as a target in COVID-19?》
    • 来源专题：COVID-19科研动态监测
    • 编译者：zhangmin
    • 发布时间：2020-04-24
    • Complement as a target in COVID-19? Antonio M. Risitano, Dimitrios C. Mastellos, Markus Huber-Lang, Despina Yancopoulou, Cecilia Garlanda, Fabio Ciceri & John D. Lambris Nature Reviews Immunology (2020) There is an urgent need to develop effective therapies for COVID-19. Here, we urge immunologists and clinicians to consider the potential of targeting the complement system in these patients. Most patients who become critically ill following infection with SARS-CoV-2, the causative agent of COVID-19, develop acute respiratory distress syndrome (ARDS)1. The deterioration of lung function has been attributed to a maladaptive immune response rather than increased viral loads. One theory is that the activation of lung-resident immune cells via pattern-recognition receptors drives the release of pro-inflammatory cytokines and extravasation of blood neutrophils and monocytes into the bronchi. These cells may disrupt the air–blood barrier by causing collateral tissue damage, particularly to airway epithelial cells and vascular endothelial cells, which express the ACE2 entry receptor for SARS-CoV-2; the damage of vascular endothelial cells may account for thrombotic microangiopathies.
    130浏览量
    原文链接